Oral booster probiotic bifidobacteria in SARS-COV-2 patients

Basit Öğe Kaydı
dc.authoridBilen, Omer/0000-0001-7198-8421en_US
dc.authoridBozkurt, Hüseyin S/0000-0003-2097-2950en_US
dc.contributor.authorBozkurt, Hüseyin S.
dc.contributor.authorBilen, Omer
dc.date.accessioned2024-07-12T21:37:26Z
dc.date.available2024-07-12T21:37:26Z
dc.date.issued2021en_US
dc.department[Belirlenecek]en_US
dc.description.abstractOral booster-single strain probiotic bifidobacteria could be a potential strategy for SARS-CoV-2. This study aims to evaluate the role of oral probiotic Bifidobacterium on moderate/severe SARS-CoV-2 inpatients. In this single-center study, we analyzed data of 44 moderate/severe inpatients with diagnosed COVID-19 in Istanbul Maltepe University Medical Faculty Hospital, 2020 from 1 November 2020 to 15 December 2020. Clinical and medication features were compared and analyzed between patients with or without probiotic. In result, 19 of the 44 patients (43.18%) who were administrated with oral booster-single strain probiotic were discharged with the median inpatient day of 7.6 days which were significantly shorter than those of patients without probiotic. There were significant differences in inpatient days, radiological improvement at day 6 and week 3, and reduction in interleukin-6 levels in those receiving oral probiotic therapy. Although the mortality rate was 5% in the probiotic group, it was 25% in the non-probiotic group. Booster-single strain probiotic bifidobacteria could be an effective treatment strategy for moderate/severe SARS-CoV-2 inpatients to reduce the mortality and length of stay in hospital.en_US
dc.identifier.doi10.1177/20587384211059677
dc.identifier.issn0394-6320
dc.identifier.issn2058-7384
dc.identifier.pmid34818923en_US
dc.identifier.scopus2-s2.0-85120455232en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1177/20587384211059677
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6770
dc.identifier.volume35en_US
dc.identifier.wosWOS:000726709000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofInternational Journal of Immunopathology And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKY04112
dc.subjectSars-Cov-2en_US
dc.subjectProbioticen_US
dc.subjectBifidobacteriaen_US
dc.titleOral booster probiotic bifidobacteria in SARS-COV-2 patientsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu